Amy Kinnamon, Senior Director Thought Leader Liaison Managed Care Oncology at MJH Life Sciences, shared a post on LinkedIn:
“The future of cancer care isn’t just about breakthrough therapies – it’s about how we apply them, scale them, and ensure patients can actually access them.
Last week in Phoenix, the American Journal of Managed Care’s ‘Pioneering the Next Era of Cancer Care’ event brought together leaders to tackle some of the field’s most pressing challenges:
As treatment options expand in multiple myeloma, sequencing advanced therapies is becoming more complex-while managing toxicity at scale remains a real-world challenge.
Bispecific therapies are evolving rapidly, but the biology-and operational realities-differ significantly between hematologic malignancies and solid tumors. Health systems must adapt quickly.
Translating academic innovation into community practice isn’t automatic. Success depends on overcoming real barriers-and learning from systems already doing it well.
In breast cancer, precision medicine brings both opportunity and complexity, especially as resistance emerges and treatment decisions become more nuanced. Access to biomarker testing remains a critical hurdle, particularly when navigating payer requirements.
The common thread? Innovation without access and operational readiness falls short. Bridging that gap is where the next era of cancer care will be defined.”
Other articles featuring Amy Kinnamon on OncoDaily.
